down arrow

Outlook Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US69012T2069
USD
2.06
0.23 (12.57%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.932.10

52 Week

0.793.39
Valuation
Technical
Day's Volume

CASH

370.0 k

Shareholding (Mar 2025)

FII

5.22%

Held by 23 FIIs

DII

87.3%

Held by 9 DIIs

Promoter

0.00%

How big is Outlook Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Outlook Therapeutics, Inc. has a market capitalization of 72.42 million and reported net sales of 0.00 million with a net profit of 21.12 million over the latest four quarters. As of Sep 24, the company has shareholder's funds of -73.08 million and total assets of 28.82 million.

As of Jun 18, Outlook Therapeutics, Inc. has a market capitalization of 72.42 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is 21.12 million.<BR><BR>As of Sep 24, the reporting period for the balance sheet shows shareholder's funds of -73.08 million and total assets of 28.82 million.

Read More

What does Outlook Therapeutics, Inc. do?

22-Jun-2025

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing biosimilar therapeutics, particularly monoclonal antibodies, in immunology and oncology. It has a market cap of USD 72.42 million and reported a net profit loss of USD 46 million as of March 2025.

Overview: <BR>Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing biosimilar therapeutics, particularly monoclonal antibodies, in the immunology and oncology sectors. The company operates within the Pharmaceuticals & Biotechnology industry and has a market cap of USD 72.42 Million.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -46 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 72.42 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.79 <BR>Return on Equity: 233.83% <BR>Price to Book: -2.23<BR><BR>Contact Details: <BR>Address: 4260 U.S. Route 1, MONMOUTH JUNCTION NJ : 08852 <BR>Tel: ['1 609 6193990', '1 212 9152568'] <BR>Website: http://oncobiologics.com/

Read More

Who are in the management team of Outlook Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Outlook Therapeutics, Inc. includes Executive Chairman Randy Thurman, CEO Lawrence Kenyon, and Directors Gerd Auffarth, Julian Gangolli, Andong Huang, Yezan Haddadin, and Kurt Hilzinger. Kenyon holds multiple key executive roles, including President and CFO.

As of March 2022, the management team of Outlook Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Randy Thurman, who serves as the Executive Chairman of the Board.<BR>- Mr. Lawrence Kenyon, who holds multiple roles as President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Director.<BR>- Dr. Gerd Auffarth, who is a Director.<BR>- Mr. Julian Gangolli, who is also a Director.<BR>- Andong Huang, who serves as a Director.<BR>- Mr. Yezan Haddadin, who is an Independent Director.<BR>- Mr. Kurt Hilzinger, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of executive leadership and directors, with Mr. Lawrence Kenyon holding several key executive positions.

Read More

Is Outlook Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 14, 2025, Outlook Therapeutics, Inc. is rated as risky due to negative valuation ratios and poor stock performance, indicating it is overvalued compared to its peers.

As of 14 August 2025, the valuation grade for Outlook Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -2.51 and an EV to EBITDA of -1.40. Additionally, the EV to Capital Employed ratio stands at -15.46, further highlighting the company's financial challenges.<BR><BR>In comparison to its peers, Outlook Therapeutics, Inc. has a less favorable position, with ADC Therapeutics SA showing a more negative P/E of -2.4050 and Kinnate Biopharma, Inc. being rated fair with an EV to EBITDA of 0.2381. The company's stock performance has been notably poor, with a 1-year return of -83.31% compared to the S&P 500's positive return of 17.14%, reinforcing the notion that the stock is currently overvalued.

Read More

Is Outlook Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Outlook Therapeutics, Inc. shows a neutral technical trend with mixed signals, including a bearish weekly MACD and a significant 1-year return of -83.31%, underperforming the S&P 500's 17.14%.

As of 9 September 2025, the technical trend for Outlook Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish trend. The RSI indicates no signal on the weekly timeframe but is bullish on the monthly. Moving averages are mildly bullish on the daily, but Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. KST is mildly bearish weekly and bearish monthly, and there are no trends indicated by Dow Theory or OBV.<BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -83.31% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of -23.73% and Operating profit at -194.48% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -23.56
2

Risky - Negative EBITDA

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 42 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.69

stock-summary
Return on Equity

195.01%

stock-summary
Price to Book

-1.13

Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
131.46%
0%
131.46%
6 Months
11.35%
0%
11.35%
1 Year
14.13%
0%
14.13%
2 Years
-78.21%
0%
-78.21%
3 Years
90.74%
0%
90.74%
4 Years
-92.26%
0%
-92.26%
5 Years
-90.96%
0%
-90.96%

Outlook Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Outlook Therapeutics Forms Death Cross, Signaling Bearish Trend Ahead

Outlook Therapeutics Forms Death Cross, Signaling Bearish Trend Ahead

Outlook Therapeutics, Inc. has recently encountered a technical event known as a Death Cross, indicating potential bearish market sentiment. The stock's daily moving averages and broader indicators reflect a negative trend, with a significant decline of 79.81% over the past year, underperforming the S&P 500.

Read More

Is Outlook Therapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Outlook Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish trend. The RSI indicates no signal on the weekly timeframe but is bullish on the monthly. Moving averages are mildly bullish on the daily, but Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. KST is mildly bearish weekly and bearish monthly, and there are no trends indicated by Dow Theory or OBV. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -83.31% versus the S&P 500's 17.14%....

Read More

Is Outlook Therapeutics, Inc. overvalued or undervalued?

As of 14 August 2025, the valuation grade for Outlook Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -2.51 and an EV to EBITDA of -1.40. Additionally, the EV to Capital Employed ratio stands at -15.46, further highlighting the company's financial challenges. In comparison to its peers, Outlook Therapeutics, Inc. has a less favorable position, with ADC Therapeutics SA showing a more negative P/E of -2.4050 and Kinnate Biopharma, Inc. being rated fair with an EV to EBITDA of 0.2381. The company's stock performance has been notably poor, with a 1-year return of -83.31% compared to the S&P 500's positive return of 17.14%, reinforcing the notion that the stock is currently overvalued....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-23.73%
EBIT Growth (5y)
-194.48%
EBIT to Interest (avg)
-23.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.79
Sales to Capital Employed (avg)
-0.56
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
36.73%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.51
EV to EBIT
-1.40
EV to EBITDA
-1.40
EV to Capital Employed
-15.46
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 22 Schemes (7.49%)

Foreign Institutions

Held by 23 Foreign Institutions (5.22%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -145.50% vs 314.49% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.70",
          "val2": "-19.50",
          "chgp": "19.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.30",
          "val2": "63.60",
          "chgp": "-106.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.20",
          "val2": "44.40",
          "chgp": "-145.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,462.00%",
          "val2": "0.00%",
          "chgp": "-1,046.20%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is -27.80% vs 10.74% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-71.60",
          "val2": "-53.10",
          "chgp": "-34.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.20",
          "val2": "1.60",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.30",
          "val2": "-4.30",
          "chgp": "69.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-75.40",
          "val2": "-59.00",
          "chgp": "-27.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
1.50
0.00
Operating Profit (PBDIT) excl Other Income
-15.70
-19.50
19.49%
Interest
0.00
0.00
Exceptional Items
-4.30
63.60
-106.76%
Consolidate Net Profit
-20.20
44.40
-145.50%
Operating Profit Margin (Excl OI)
-10,462.00%
0.00%
-1,046.20%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -145.50% vs 314.49% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-71.60
-53.10
-34.84%
Interest
3.20
1.60
100.00%
Exceptional Items
-1.30
-4.30
69.77%
Consolidate Net Profit
-75.40
-59.00
-27.80%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is -27.80% vs 10.74% in Sep 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Outlook Therapeutics, Inc. stock-summary
stock-summary
Outlook Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.
Company Coordinates stock-summary
Company Details
4260 U.S. Route 1 , MONMOUTH JUNCTION NJ : 08852
stock-summary
Tel: 1 609 61939901 212 9152568
stock-summary
http://oncobiologics.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."